Assessing Outcomes of Flexible Boosting of CoronaVac COVID-19 Vaccine

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. (ET), WEDNESDAY, AUGUST 10, 2022

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time http://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2022.26046?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=081022

About JAMA Network Open: JAMA Network Open is the new online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

 

About The Study: In this study using national data of nearly 14 million vaccinated individuals in Malaysia, researchers assessed the risk of symptomatic SARS-CoV-2 infection associated with two doses of the CoronaVac (Sinovac Biotech) COVID-19 vaccine plus a third dose or a Pfizer-BioNTech booster compared with two or three doses of the Pfizer-BioNTech vaccine.

Authors: Ee Vien Low, Ph.D., of the Ministry of Health Malaysia in Shah Alam, Malaysia, is the corresponding author.

 

(doi:10.1001/jamanetworkopen.2022.26046)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.